comparemela.com

Page 5 - Three Months News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 mi.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.